Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 19/20 | 0.80 |
| ▸ | CSNK1D | P48730 | 12/20 | 0.80 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18171294 | 0.89 | CSNK1E (0.80) | CSNK1ECSNK1DCREBBP | |
| SCHEMBL16722445 | 0.89 | CSNK1E (1.00) | CSNK1ECSNK1D | |
| SCHEMBL16700825 | 0.83 | CSNK1E (0.60) | CSNK1ECSNK1D | |
| SCHEMBL16699676 | 0.82 | CSNK1E (0.58) | CSNK1ECSNK1D | |
| SCHEMBL18171127 | 0.81 | CSNK1E (0.55) | CSNK1ECSNK1D | |
| SCHEMBL18183997 | 0.79 | CSNK1E (0.88) | CSNK1ECSNK1D | |
| SCHEMBL16699959 | 0.79 | CSNK1E (0.82) | CSNK1ECSNK1D | |
| SCHEMBL18184025 | 0.78 | CSNK1E (1.00) | CSNK1ECSNK1D | |
| SCHEMBL18171250 | 0.78 | CSNK1E (0.81) | CSNK1ECSNK1DCREBBP | |
| SCHEMBL16701004 | 0.76 | CSNK1E (0.68) | CSNK1ECSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598423-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160311824-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311824-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1A1, CSNK1E, CSNK1G1 | CSNK1E 2/4885CSNK1D 6/4885CREBBP 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.